Drug lookup | Fillwise

PILOCARPINE HCL

Form:

6 of 6 products shown

2 general benefit · 4 not a benefit

Other products in the same Health Canada class (N07A) — coverage varies; not interchangeable

Bethanechol chloride (Duvoid): general benefit
Pyridostigmine (Mestinon): general benefit

Isopto Carpine · DIN 00000868 · 2% · Oph Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Isopto Carpine · DIN 00000868 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-12-08 · brand ISOPTO CARPINE · ATC S01EB01 PILOCARPINE · form Solution · route Ophthalmic · ingredients PILOCARPINE HYDROCHLORIDE 2 % · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Isopto Carpine: Formulary list price $0.3386/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3386 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2375 · Verify on the e-Formulary ↗ (DIN 00000868)

Source record

DIN 00000868: Isopto Carpine Raw flags: sec3=Y Item: 522000011; group id 604; item number 1564; lccId None; manufacturer id NOV Source form: Oph Sol; strength: 2% Recorded listing: General benefit Source prices (unrounded): $0.3386; ministry $0.3386 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00000868 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2375

Interchangeable products

Pilocarpine · DIN 02023741 · not recorded

Shortage status: resolved shortage (ended 2022-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00000868

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Pilocarpine · DIN 02509571 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Jamp Pilocarpine · DIN 02509571 Manufacturer: Jamp Pharma Corporation; listing date 2021-05-31 Health Canada: Marketed since 2021-04-30 · brand JAMP PILOCARPINE · ATC N07AX01 PILOCARPINE · form Tablet · route Oral · ingredients PILOCARPINE HYDROCHLORIDE 5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Pilocarpine: Formulary list price $1.1708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99887 · Verify on the e-Formulary ↗ (DIN 02509571)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02509571). DIN 02509571: Jamp Pilocarpine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 120400032; group id 195; item number 0359; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.1708; ministry $1.1708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509571 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99887

Interchangeable products

M-Pilocarpine · DIN 02496119 · $1.1708 Salagen · DIN 02216345 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509571

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Pilocarpine · DIN 02496119 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

M-Pilocarpine · DIN 02496119 Manufacturer: Mantra Pharma Inc.; listing date 2020-07-31 Health Canada: Marketed since 2021-06-14 · brand M-PILOCARPINE · ATC N07AX01 PILOCARPINE · form Tablet · route Oral · ingredients PILOCARPINE HYDROCHLORIDE 5 MG · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Pilocarpine: Formulary list price $1.1708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98599 · Verify on the e-Formulary ↗ (DIN 02496119)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02496119). DIN 02496119: M-Pilocarpine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 120400032; group id 195; item number 0359; lccId None; manufacturer id MAT Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.1708; ministry $1.1708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496119 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98599

Interchangeable products

Jamp Pilocarpine · DIN 02509571 · $1.1708 Salagen · DIN 02216345 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salagen · DIN 02216345 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Salagen · DIN 02216345 Manufacturer: Amdipharm Limited; listing date 2013-05-31 Health Canada: Marketed since 2020-07-21 · brand SALAGEN · ATC N07AX01 PILOCARPINE · form Tablet · route Oral · ingredients PILOCARPINE HYDROCHLORIDE 5 MG · company Amdipharm limited · schedule Prescription

Check this DIN again · Health Canada product record

Salagen: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43182 · Verify on the e-Formulary ↗ (DIN 02216345)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02216345). DIN 02216345: Salagen Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 120400032; group id 195; item number 0359; lccId None; manufacturer id AMD Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216345 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43182

Interchangeable products

Jamp Pilocarpine · DIN 02509571 · $1.1708 M-Pilocarpine · DIN 02496119 · $1.1708

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pilocarpine · DIN 02023741 · 2% · Oph Sol

Listed, not a benefitDormant since 2019-09-24 · checked 2026-09-02 · What does dormant mean?

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pilocarpine · DIN 02023741 Manufacturer: Pharma Stulln Inc.; listing date 1999-04-15 Health Canada: Dormant since 2019-09-24 · brand PILOCARPINE · ATC S01EB01 PILOCARPINE · form Solution · route Ophthalmic · ingredients PILOCARPINE HYDROCHLORIDE 2 % · company Pharma stulln inc. · schedule Prescription

Check this DIN again · Health Canada product record

Pilocarpine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16217 · Verify on the e-Formulary ↗ (DIN 02023741)

Source record

DIN 02023741: Pilocarpine Raw flags: notABenefit=Y, sec3=Y Item: 522000011; group id 604; item number 1564; lccId None; manufacturer id PHS Source form: Oph Sol; strength: 2% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02023741 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16217

Interchangeable products

Isopto Carpine · DIN 00000868 · $0.3386

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2019-09-24 — choose a marketed DIN from the same-category list.

Isopto Carpine · DIN 00000884 · 4% · Oph Sol

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-18 — choose a marketed DIN from the same-category list.Discontinued 2022-07-18 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-18 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Isopto Carpine · DIN 00000884 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-07-18 · brand ISOPTO CARPINE · ATC S01EB01 PILOCARPINE · form Liquid · route Ophthalmic · ingredients PILOCARPINE HYDROCHLORIDE 4 % · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Isopto Carpine: Formulary list price $0.3360/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3360 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00000884: Isopto Carpine Raw flags: sec3=Y Item: 522000009; group id 604; item number 1565; lccId None; manufacturer id NOV Source form: Oph Sol; strength: 4% Recorded listing: General benefit Source prices (unrounded): $0.3360; ministry $0.3360 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00000884 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2374

Shortage status: discontinued (2022-07-05, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00000884

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2022-07-18 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

DONEPEZIL HCL

· 48 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04

Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (52:20 Miotics) and how they are covered

No products matched this class search: “52:20”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS ISOPTO® CARPINE (Pilocarpine hydrochloride ophthalmic solution, USP) is indicated for the reduction of intraocular pressure. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Elderly patients may be at a higher risk for pilocarpine-induced mental status changes, including psychosis and dementia of the Alzheimer type. https://pdf.hres.ca/dpd_pm/00072411.PDF PM date: DEC 31, 1959 Source product: ISOPTO CARPINE; DIN 00000868; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Isopto Carpine · DIN 00000884 Shortage status: discontinued (2022-07-05, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00000884

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Jamp Pilocarpine, M-Pilocarpine, Salagen, Pilocarpine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026